Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer

Open access

Published version of a preprint

Abstract

Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key genetic step that complements activation of KRAS in promoting the development and malignant growth of pancreatic ductal adenocarcinoma (PDAC). However, pharmacologic restoration of p16INK4A function with inhibitors of CDK4 and CDK6 (CDK4/6) has shown limited clinical efficacy in PDAC. Here, we found that concurrent treatment with both a CDK4/6 inhibitor (CDK4/6i) and an ERK–MAPK inhibitor (ERKi) synergistically suppresses the growth of PDAC cell lines and organoids by cooperatively blocking CDK4/6i-induced compensatory upregulation of ERK, PI3K, antiapoptotic signaling, and MYC expression. On the basis of these findings, a Phase I clinical trial was initiated to evaluate the ERKi ulixertinib in combination with the CDK4/6i palbociclib in patients with advanced PDAC (NCT03454035). As inhibition of other proteins might also counter CDK4/6i-mediated signaling changes to increase cellular CDK4/6i sensitivity, a CRISPR-Cas9 loss-of-function screen was conducted that revealed a spectrum of functionally diverse genes whose loss enhanced CDK4/6i growth inhibitory activity. These genes were enriched around diverse signaling nodes, including cell-cycle regulatory proteins centered on CDK2 activation, PI3K–AKT–mTOR signaling, SRC family kinases, HDAC proteins, autophagy-activating pathways, chromosome regulation and maintenance, and DNA damage and repair pathways. Novel therapeutic combinations were validated using siRNA and small-molecule inhibitor–based approaches. In addition, genes whose loss imparts a survival advantage were identified (e.g., RB1, PTEN, FBXW7), suggesting possible resistance mechanisms to CDK4/6 inhibition. In summary, this study has identified novel combinations with CDK4/6i that may have clinical benefit to patients with PDAC. Significance: CRISPR-Cas9 screening and protein activity mapping reveal combinations that increase potency of CDK4/6 inhibitors and overcome drug-induced compensations in pancreatic cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-22-0391

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 168

Metadata

Authors
Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., Ozkan-Dagliyan, I., Baldelli, E., Calvert, V., Pierobon, M., Sorrentino, J. A., Beelen, A. P., Bublitz, N., Lüthen, M., Wood, K. C., Petricoin, E. F., Sers, C., McRee, A. J., Cox, A. D., & Der, C. J.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • 3Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • George Mason University (US)
  • 8G1 Therapeutics, Research Triangle Park, North Carolina.
  • German Cancer Research Center (DE)
  • Duke University (US)
Corresponding author
Der, Channing J.
Venue
Cancer Research
Published
2022-11-08
Volume
83
Issue
1
Pages
141-157
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W4308510057
Cited by
168
References
60
Citations by year
2026: 32 · 2025: 62 · 2024: 43 · 2023: 31
FWCI
14.23
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • National Cancer Institute (T32CA009156, F32CA221005, F32CA239328, P50CA196510, R37CA251877, F32CA232529, R01CA42978, R01CA175747, R01CA223775, U01CA199235, P01CA203657, R35CA232113)
  • American Cancer Society (PF-18-061, PF-20-069, PF-22-066-01)
  • Royster Society of Fellows
  • Pancreatic Cancer Action Network (15-70-25-BRYA, 15-90-25-DER)
  • Sky Foundation
  • Deutsche Forschungsgemeinschaft (DFG PA 3051/1-1)
  • Slomo and Cindy Silvian Foundation
  • National Institutes of Health (CA203657)
  • U.S. Department of Defense (W81XWH-15-1-0611)
  • Lustgarten Foundation (388222)
  • Julie M. Brown and Christina Gianoplus Colon Cancer Foundation
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
CDK4/6 inhibitors, p16INK4a, CDKN2A loss, ulixertinib, palbociclib, combination therapy, compensatory signaling, PI3K/AKT/mTOR pathway, c-Myc, CRISPR-Cas9 loss-of-function screen, drug resistance, RB1, PTEN, FBXW7, Src family kinases, histone deacetylase, autophagy, DNA damage and repair, cell cycle regulation
MeSH terms
Humans, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Phosphatidylinositol 3-Kinases, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-22-0391
The paper
Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., Ozkan-Dagliyan, I., Baldelli, E., Calvert, V., Pierobon, M., Sorrentino, J. A., Beelen, A. P., Bublitz, N., Lüthen, M., Wood, K. C., . . . Der, C. J. (2023). Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-22-0391

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.